Additionally, an ELISA was performed to measure EphB4 phosphorylation in PC3 prostate cancer cells and EphB4 stably expressing HEK293 cells following treatment with commercially available ephrinB2-Fc (ephrinB2-Fc R&D), ephrinB2-Fc-His, and Fc-TNYL-RAW-GS (Supplementary Fig. 11B). Here, EFNB2 is linked to prostate carcinoma.